EMA Authorised: Vyjuvek (Beremagene geperpavec) — Krystal Biotech Netherlands B.V.

View source ↗

Summary

The EMA authorises Vyjuvek (beremagene geperpavec) for Epidermolysis Bullosa Dystrophica.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa Dystrophica

Drugs mentioned

• Vyjuvek

Snippet

Status: Authorised. Therapeutic area: Epidermolysis Bullosa Dystrophica. MAH: Krystal Biotech Netherlands B.V.. Decision date: 08/06/2026. Orphan medicine